KAIROS

VISOLYR

AGENTIC ADAPTIVE INTELLIGENCE™

Navigating moments that matter.

KAIROS™ by Visolyr® unifies purpose-built AI agents to transform cardiometabolic care, helping clinicians detect early disease signs and act before complications occur. Our proactive insights promote healthier populations and empower health systems to provide cost-effective, compassionate care.

Early Detection

Identify cardiometabolic risks sooner

Improved Outcomes

Reduce complications and hospitalizations

Proactive Insights

Actionable alerts for clinicians

Cost-Effective Care

Support sustainable health systems

VISION

A future in which every person receives care that is proactive, tailored, and effective

MISSION

Reimagine healthcare by surfacing early signs of disease risk and providing actionable insights that clinicians can independently review and apply in care decisions

📞 **+1.703.861.9897** 🌐 **www.visolyr.io** 📧 **info@visolyr.io**

Cardiometabolic Health Navigator

KAIROS
VISOLYR

Problem

Traditional Care Plans are static, educational documents that patients struggle to follow consistently. Clinicians lack real-time visibility into adherence, risk changes, and day-to-day patient behaviors, making proactive intervention difficult.

Solution

Visolyr transforms Care Plans into an adaptive, personalized care companion that guides daily actions, goals, and progress tracking. A clinician-facing dashboard highlights blood pressure trends, gaps in adherence, and symptom changes, enabling timely decisions and targeted outreach.

Capabilities and Features

- Personalized daily actions, SMART goals, and biometric tracking improve adherence
- Real-time visibility helps clinicians intervene earlier and more effectively
- Adaptive, AI-generated care plans evolve with each patient's risk profile
- Seamlessly integrates into clinical workflows
- Demonstrates the power of Visolyr's Agentic Adaptive Intelligence™ to deliver dynamic, patient-specific care experiences

Value Proposition & Benefits

For Clinicians:

- Earlier detection of uncontrolled BP, missed meds, and emerging risk
- Reduced time spent piecing together fragmented data
- Clearer decision-making supported by real-time patient updates

For Patients:

- Higher adherence through personalized, achievable daily actions
- Better understanding of what to do and why, reducing confusion
- More consistent self-management and confidence in care

For Health Systems:

- Fewer downstream complications tied to hypertension and diabetes
- Reduced acute care utilization through earlier intervention
- Improved quality scores and value-based performance

📞 +1.703.861.9897 🌐 www.visolyr.io 📧 info@visolyr.io

Patient Safety Intelligence

KAIROS
VISOLYR

Problem

Adverse event detection is manual, burdensome, and error-prone. Clinicians struggle to synthesize EMR data, medication history, and FAERS signals into clear, actionable insights. Reporting often lacks context and delays patient safety interventions.

Solution

Visolyr combines graph-based inferencing with LLM reasoning to automatically detect adverse events, interpret clinical signals, and produce structured, MedWatch-ready reports enriched with confidence scoring and contextual insights.

Capabilities and Features

- Automated detection and report generation reduce burden and improve safety
- Real-time FAERS integration enables rapid signal lookup and trend analysis
- Supports chronic disease and pharmacovigilance analytics using correlated clinical, claims, and safety data
- Produces explainable outputs clinicians can trust
- Creates a flexible framework that extends to compliance, safety, and precision medicine use cases

Value Proposition & Benefits

For Clinicians:

- Dramatically reduced administrative burden of AE documentation
- Faster recognition of medication-related risks
- Clear, explainable summaries that support clinical judgment

For Patients:

- Safer medication management with timely risk detection
- Reduced likelihood of preventable adverse drug reactions
- Better communication and understanding of medication risks

For Health Systems:

- Stronger patient safety oversight and regulatory compliance
- Fewer adverse events leading to costly ED visits or readmissions
- Improved pharmacovigilance across populations and treatment

📞 +1.703.861.9897 🌐www.visolyr.io 📧info@visolyr.io

Population Health Dashboard

KAIROS
VISOLYR

Problem

Care teams face a fragmented view of patient health, struggling to identify and manage high-risk individuals effectively. Critical information is scattered across various systems like EMR, lab results, claims, and social determinants of health (SDoH) data. This disjointed approach hinders proactive intervention, complicates outreach prioritization, impedes addressing patient-specific barriers, and makes tracking care plans difficult. These challenges are particularly acute in rural and community clinics due to significant gaps in resource coordination.

Solution

Visolyr provides a single, intelligent workspace for population health. It identifies high- and rising-risk patients by synthesizing diverse data sources, surfaces actionable next steps for care teams, and integrates social determinants and coverage navigation tools to streamline care coordination. This enables health systems to deliver targeted, efficient, and equitable care across their patient populations.

Capabilities and Features

Unified filtering by clinic, payer, condition, or risk level provides granular insights into patient populations.

Actionable guidance for outreach, referral coordination, and barrier resolution streamlines care team workflows.

Integrated SDoH data highlights critical social barriers such as transportation, housing, or financial issues.

Real-world sample: 562 of 690 rural patients flagged as high or rising risk with automated next-step recommendations.

Safety Intelligence module auto-generates FDA-ready reports, enhancing regulatory compliance and patient safety.

Insurance verification and benefit summaries streamline navigation for both patients and providers.

Value Proposition & Benefits

For Clinicians:

- Immediate visibility into which patients need attention most, enabling proactive care.
- Streamlined outreach using prioritized task lists and intelligent recommendations.
- Reduced workload by automating manual chart review and risk identification processes.

For Patients:

- More timely follow-ups and outreach from care teams, improving engagement.
- Greater access to essential transportation, financial, or social support resources.
- Higher referral completion rates and improved continuity of care.

For Health Systems:

- Stronger performance in chronic care management and population health metrics.
- Reduced no-shows, fewer care gaps, and better management of high-risk cases.
- Improved operational efficiency by focusing resources on the highest-risk groups.

📞 +1.703.861.9897 🌐 www.visolyr.io 📧 info@visolyr.io

AI Image Analysis for Diabetic Retinopathy

KAIROS
VISOLYR

Problem

Early diabetic eye disease can go undetected due to limited specialist access, variability in screening quality, and lack of explainable diagnostic support that both clinicians and patients can easily understand.

Solution

Visolyr's DR module uses deep learning, Grad-CAM explainability, and generative AI to classify retinal fundus images, highlight affected regions, and generate structured clinical and patient-friendly narratives.

Capabilities and Features

- Early detection support with interpretable heatmaps and structured findings
- Built on NVIDIA Clara multimodal medical imaging tools
- Provides differential context, urgency scoring, and care pathway recommendations
- Generates plain-language and clinician-ready summaries to improve communication
- Demonstrates how agent-driven, explainable AI enhances proactive and personalized eye care

Value Proposition & Benefits

For Clinicians:

- Faster screening with clear visual explanations
- Higher confidence in identifying early disease or ruling it out
- Consistent, reliable support when specialist access is limited

For Patients:

- Earlier identification of eye disease before symptoms progress
- Easy-to-understand summaries that improve follow-through
- Reduced anxiety through clear explanations and next steps

For Health Systems:

- Lower preventable vision-loss events and associated long-term costs
- Increased screening compliance, especially in primary care settings
- Ability to expand eye screening without requiring more specialists

📞 +1.703.861.9897 🌐 www.visolyr.io 📧 info@visolyr.io

MASLD Screening Agent

KAIROS
VISOLYR

Problem

Metabolic dysfunction–associated steatotic liver disease (MASLD) impacts over a third of adults but is critically underdiagnosed in early stages. Clinicians face fragmented patient data, struggling to consolidate liver function tests, metabolic risk factors, and coded conditions for fibrosis risk assessment. Inconsistent FIB-4 calculations, scattered imaging results, and buried risk signals across EMR entries lead to patients progressing to advanced fibrosis unnoticed, resulting in avoidable complications and significantly higher healthcare costs.

Solution

Visolyr's MASLD Screening Agent revolutionizes early detection by automating EMR data analysis. It normalizes diagnoses via UMLS, calculates real-time FIB-4 scores, and generates evidence-based recommendations. This provides clinicians with a unified view of patient liver health, metabolic risk, and fibrosis severity, enabling earlier intervention, improved outcomes, and reduced healthcare burden.

Capabilities and Features

Automated FIB-4 Calculation using age, AST, ALT, and platelets drawn directly from EMR labs.

UMLS-powered diagnosis normalization to identify MASLD-relevant conditions across ICD-10 and SNOMED codes.

Detection of key metabolic drivers, including type 2 diabetes, obesity, dyslipidemia, and hypertension.

AI-generated clinical reasoning providing concise summaries of risks, care gaps, and recommended next steps.

Second-line test guidance (VCTE/FibroScan, ELF) based on personalized risk category.

Clear risk stratification (low, indeterminate, high fibrosis risk) aligned with current clinical guidelines.

Value Proposition & Benefits

For Clinicians:

- Earlier and more reliable identification of MASLD and high-risk fibrosis.
- Automated extraction of labs, conditions, and risk factors significantly reduces manual chart review time.
- Clear, guideline-consistent next-step guidance aligned with AASLD and AACE recommendations.
- Improved confidence in managing diagnostic uncertainty, especially for indeterminate FIB-4 cases.

For Patients:

- Better understanding of their liver health and associated metabolic risks.
- More timely evaluation and prevention of fibrosis progression, leading to better long-term outcomes.
- Clearer follow-up instructions, improving adherence to necessary labs, imaging, and lifestyle recommendations.
- Reduced fear and confusion through simplified, actionable explanations of their condition and treatment plan.

For Health Systems:

- Reduced downstream costs by enabling earlier detection and management of liver fibrosis.
- Fewer cirrhosis-related hospital admissions and emergency department visits.
- Stronger performance in value-based contracts tied to chronic disease management metrics.
- Scalable approach to risk stratification across large populations with minimal additional clinician burden.

📞 +1.703.861.9897 🌐 www.visolyr.io 📧 info@visolyr.io